<DOC>
	<DOCNO>NCT02837575</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy therapeutic DNA vaccine adult symptomatic herpes simplex virus type 2 ( i.e. , genital herpes ) .</brief_summary>
	<brief_title>Safety Efficacy Study Herpes Simplex Virus Type 2 ( HSV-2 ) Therapeutic DNA Vaccine</brief_title>
	<detailed_description>To evaluate safety efficacy 4 dos VCL-HB01 , therapeutic HSV plasmid DNA vaccine formulate VaxfectinÂ® HSV-2-seropositive adult report history symptomatic genital herpes least one year .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>HSV2 seropositive A minimum 1 year report history genital herpes recurrence . History receive investigational HSV vaccine Chronic illness subject 's immune system suspect impaired altered , cancer , autoimmune condition , diabetes Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HSV-2</keyword>
	<keyword>Genital Herpes</keyword>
	<keyword>Herpes</keyword>
	<keyword>Herpes Simplex Virus , Type 2</keyword>
</DOC>